ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption

Published on February 25, 2026 at 6:19 am by Maham Fatima in News

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best high volume stocks to invest in now. On February 23, ImmunityBio reported exceptional financial growth for 2025, headlined by a 700% year-over-year increase in net product revenue for its lead immunotherapy, ANKTIVA, which reached $113 million. This surge was supported by a 750% increase in unit sales volume and a 20% sequential growth in Q4, reflecting strong clinical adoption.

While the company posted a net loss of $351.4 million for the year, this represented a reduction from 2024 losses, primarily due to the significant revenue offset and lower administrative expenses, even as research and development costs rose to $218.6 million to support its expanding clinical pipeline. The company rapidly established a global commercial footprint, securing regulatory authorizations in 33 countries across four major jurisdictions, including the US, UK, EU, and Saudi Arabia.

Notably, Saudi Arabia became the first jurisdiction to approve ANKTIVA for a second indication, metastatic non-small cell lung cancer, marking the drug’s first validation in solid tumors beyond bladder cancer. To support this expansion, ImmunityBio Inc. (NASDAQ:IBRX) formed partnerships with Accord Healthcare in Europe and BioPharma & Cigalah in the Middle East, while establishing new subsidiaries in Dublin and Riyadh. ImmunityBio is now advancing a three-year global strategy that positions ANKTIVA as the backbone for its Cancer BioShield platform, which targets various tumor types, including glioblastoma, pancreatic cancer, and lymphoma.

ImmunityBio Inc. (NASDAQ:IBRX) is a biotechnology company that innovates, develops, and commercializes next-gen immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.